Triptorelin ( DrugBank: Triptorelin )

2 diseases

ID	Disease name (Link within this page)	Number of trials
49	Systemic lupus erythematosus	1
76	Pituitary gonadotropin secretion hyperthyroidism	5

49. Systemic lupus erythematosus

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00124514 (ClinicalTrials.gov)	June 2003	26/7/2005	Triptorelin for Ovary Protection in Childhood Onset Lupus		Systemic Lupus Erythematosus	Drug: Triptorelin pamoate	Children's Hospital Medical Center, Cincinnati	Watson Pharmaceuticals	Completed	9 Years	21 Years	Female	30	Phase 2	United States;Brazil

First Previous1Next Last

76. Pituitary gonadotropin secretion hyperthyroidism

Clinical trials : 29 / Drugs : 44 - (DrugBank : 14) / Drug target genes : 5 - Drug target pathways : 15

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05029622 (ClinicalTrials.gov)	August 10, 2021	9/8/2021	A Study to Assess the Efficacy and Safety of the Triptorelin6-month Formulation in Paediatric Partic ...	A Phase III, Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of the Trip ...	Central Precocious Puberty	Drug: Triptorelin Pamoate	Ipsen	NULL	Completed	N/A	10 Years	All	66	Phase 3	China
2	NCT04736602 (ClinicalTrials.gov)	March 27, 2021	29/1/2021	Efficacy and Safety Study of Triptorelin3-Month Formulation in Chinese Children With Central Precoci ...	An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin3-month ...	Central Precocious Puberty	Drug: Triptorelin pamoate 15mg	Ipsen	NULL	Completed	N/A	10 Years	All	32	Phase 3	China
3	NCT01467882 (ClinicalTrials.gov)	April 2012	7/11/2011	Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin6-month Formulation in Patients With Centr ...	An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of T ...	Central Precocious Puberty	Drug: Triptorelin	Debiopharm International SA	NULL	Completed	2 Years	9 Years	All	44	Phase 3	United States;Chile;Mexico
4	NCT00438217 (ClinicalTrials.gov)	May 2006	21/2/2007	Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Child ...	Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Child ...	Central Precocious Puberty	Drug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists)	University of Pisa	NULL	Recruiting	1 Year	18 Years	Both	100	Phase 4	Italy
5	EUCTR2015-001607-30-Outside-EU/EEA (EUCTR)		24/04/2015	Triptorelin 6-month formulation for children who mature too early because of a brain hormone	An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of t ...	Central Precocious Puberty MedDRA version: 18.0;Level: PT;Classification code 10058084;Term: Precoci ...	INN or Proposed INN: TRIPTORELIN Other descriptive name: Triptorelin embonate, Triptorelin pamoate	Debiopharm International, S.A.	NULL	NA			Female: yes Male: yes	44		United States;Chile;Mexico

First Previous1Next Last